Annemiek M van Maldegem1, Aparna Bhosale1, Hans J Gelderblom2, Pancras Cw Hogendoorn3, Andrew B Hassan1,4. 1. Department of Oncology, Oxford Cancer and Haematology Centre, Churchill Hospital, University of Oxford, Oxford OX3 7LJ, UK. 2. Department of Clinical Oncology, Leiden University Medical Center, Leiden, PO Box 9600, 2600 RC Leiden, The Netherlands. 3. Department of Pathology, Leiden University Medical Center, Leiden, PO Box 9600, 2600 RC Leiden, The Netherlands. 4. Sir William Dunn School of Pathology, South Parks Road, University of Oxford, Oxford OX1 3RE, UK.
Abstract
BACKGROUND: High grade primary bone sarcomas are rare cancers that affect mostly children and young adults. Osteosarcoma and Ewing sarcoma are the most common histological subtypes in this age group, with current multimodality treatment strategies achieving 55-70% overall survival. As there remains an urgent need to develop new therapeutic interventions, we have reviewed published phase I/II trials that have been reported for osteosarcoma and Ewing sarcoma in the last twenty years. RESULTS: We conducted a literature search for clinical trials between 1990 and 2010, either for trials enrolling bone sarcoma patients as part of a general sarcoma indication or trials specifically in osteosarcoma and Ewing sarcoma. We identified 42 clinical trials that fulfilled our search criteria for general sarcoma that enrolled these patient groups, and eight and twenty specific trials for Ewing and osteosarcoma patients, respectively. For the phase I trials which enrolled different tumour types our results were incomplete, because the sarcoma patients were not mentioned in the PubMed abstract. A total of 3,736 sarcoma patients were included in these trials over this period, 1,114 for osteosarcoma and 1,263 for Ewing sarcoma. As a proportion of the worldwide disease burden over this period, these numbers reflect a very small percentage of the potential patient recruitment, approximately 0.6% for Ewing sarcoma and 0.2% for osteosarcoma. However, these data show an increase in recent activity overall and suggest there is still much room for improvement in the current trial development structures. CONCLUSION: Lack of resources and commercial investment will inevitably limit opportunity to develop sufficiently rapid improvements in clinical outcomes. International collaboration exists in many well founded co-operative groups for phase III trials, but progress may be more effective if there were also more investment of molecular and translational research into disease focused phase I/II clinical trials. Examples of new models for early translational and early phase trial collaboration include the European based EuroBoNeT network, the Sarcoma Alliance for Research through Collaboration network (SARC) and the new European collaborative translational trial network, EuroSarc.
BACKGROUND: High grade primary bone sarcomas are rare cancers that affect mostly children and young adults. Osteosarcoma and Ewing sarcoma are the most common histological subtypes in this age group, with current multimodality treatment strategies achieving 55-70% overall survival. As there remains an urgent need to develop new therapeutic interventions, we have reviewed published phase I/II trials that have been reported for osteosarcoma and Ewing sarcoma in the last twenty years. RESULTS: We conducted a literature search for clinical trials between 1990 and 2010, either for trials enrolling bone sarcomapatients as part of a general sarcoma indication or trials specifically in osteosarcoma and Ewing sarcoma. We identified 42 clinical trials that fulfilled our search criteria for general sarcoma that enrolled these patient groups, and eight and twenty specific trials for Ewing and osteosarcomapatients, respectively. For the phase I trials which enrolled different tumour types our results were incomplete, because the sarcomapatients were not mentioned in the PubMed abstract. A total of 3,736 sarcomapatients were included in these trials over this period, 1,114 for osteosarcoma and 1,263 for Ewing sarcoma. As a proportion of the worldwide disease burden over this period, these numbers reflect a very small percentage of the potential patient recruitment, approximately 0.6% for Ewing sarcoma and 0.2% for osteosarcoma. However, these data show an increase in recent activity overall and suggest there is still much room for improvement in the current trial development structures. CONCLUSION: Lack of resources and commercial investment will inevitably limit opportunity to develop sufficiently rapid improvements in clinical outcomes. International collaboration exists in many well founded co-operative groups for phase III trials, but progress may be more effective if there were also more investment of molecular and translational research into disease focused phase I/II clinical trials. Examples of new models for early translational and early phase trial collaboration include the European based EuroBoNeT network, the Sarcoma Alliance for Research through Collaboration network (SARC) and the new European collaborative translational trial network, EuroSarc.
Authors: Antonio Jimeno; Najat C Daw; Maria L Amador; George Cusatis; Peter Kulesza; Mark Krailo; Ashish M Ingle; Susan M Blaney; Peter Adamson; Manuel Hidalgo Journal: Pediatr Blood Cancer Date: 2007-09 Impact factor: 3.167
Authors: Mason Bond; Mark L Bernstein; Alberto Pappo; Kirk R Schultz; Mark Krailo; Susan M Blaney; Peter C Adamson Journal: Pediatr Blood Cancer Date: 2008-02 Impact factor: 3.167
Authors: Marie-Cecile Le Deley; Olivier Delattre; Karl-Ludwig Schaefer; Sue A Burchill; Gabriele Koehler; Pancras C W Hogendoorn; Thomas Lion; Christopher Poremba; Julien Marandet; Stelly Ballet; Gaelle Pierron; Samantha C Brownhill; Michaela Nesslböck; Andreas Ranft; Uta Dirksen; Odile Oberlin; Ian J Lewis; Alan W Craft; Heribert Jürgens; Heinrich Kovar Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Nita L Seibel; Mark Krailo; Zhengjia Chen; John Healey; Philip P Breitfeld; Richard Drachtman; Brian Greffe; James Nachman; Helen Nadel; Judith K Sato; Paul A Meyers; Gregory H Reaman Journal: Cancer Date: 2007-04-15 Impact factor: 6.860
Authors: Fariba Navid; Victor M Santana; Catherine A Billups; Thomas E Merchant; Wayne L Furman; Sheri L Spunt; Alvida M Cain; Bhaskar N Rao; Gregory A Hale; Alberto S Pappo Journal: Cancer Date: 2006-04-15 Impact factor: 6.860
Authors: Alexander J Chou; Eugenie S Kleinerman; Mark D Krailo; Zhengjia Chen; Donna L Betcher; John H Healey; Ernest U Conrad; Michael L Nieder; Michael A Weiner; Robert J Wells; Richard B Womer; Paul A Meyers Journal: Cancer Date: 2009-11-15 Impact factor: 6.860
Authors: Shana Jacobs; Elizabeth Fox; Mark Krailo; Gwen Hartley; Fariba Navid; Leonard Wexler; Susan M Blaney; Anne Goodwin; Wendy Goodspeed; Frank M Balis; Peter C Adamson; Brigitte C Widemann Journal: Clin Cancer Res Date: 2010-01-12 Impact factor: 12.531
Authors: Rochelle Bagatell; Lia Gore; Merrill J Egorin; Richard Ho; Glenn Heller; Nichole Boucher; Eleanor G Zuhowski; James A Whitlock; Stephen P Hunger; Aru Narendran; Howard M Katzenstein; Robert J Arceci; Jessica Boklan; Cynthia E Herzog; Luke Whitesell; S Percy Ivy; Tanya M Trippett Journal: Clin Cancer Res Date: 2007-03-15 Impact factor: 12.531
Authors: Vivek Subbiah; Pete M Anderson; Kalevi Kairemo; Kenneth Hess; Winston W Huh; Vinod Ravi; Najat C Daw; Neeta Somaiah; Joseph A Ludwig; Robert S Benjamin; Sant Chawla; David S Hong; Funda Meric-Bernstam; Gregory Ravizzini; Eugenie Kleinerman; Homer Macapinlac; Eric Rohren Journal: Clin Cancer Res Date: 2019-02-07 Impact factor: 12.531
Authors: A Marturano-Kruik; A Villasante; K Yaeger; S R Ambati; A Chramiec; M T Raimondi; G Vunjak-Novakovic Journal: Biomaterials Date: 2017-10-10 Impact factor: 12.479
Authors: Eugenie S Kleinerman; Razelle Kurzrock; Vivek Subbiah; Fernando F Corrales-Medina; Cynthia Herzog; Kenneth Hess; Daniela Egas-Bejar; David S Hong; Gerald Falchook; Pete Anderson; Cesar Nunez; Winston W Huh; Aung Naing; Apostolia M Tsimberidou; Jennifer Wheler; Sarina Piha Paul; Filip Janku Journal: Oncoscience Date: 2014-07-27